Formulation Design And Characterization Of Matrix Tablets
Main Article Content
Abstract
The aim of this study was to design oral controlled release lamivudine matrix tablets using hydroxypropyl methylcellulose (HPMC) as the retardant polymer, sodium alginate, acacia gum to study the effect of various formulation factors such as polymer proportion, polymer viscosity, and compression force on the in vitro release of drug. In vitro release studies were performed using (USP II) with paddle apparatus (basket method) in 900 mL of pH 6.8 phosphate buffer at 50 rpm. The release kinetics were analyzed using the zero-order model equation, Higuchi’s square-root equation, and the Ritger-Peppas empirical equation. Compatibility of the drug with various excipients was studied. Increase in compression force was found to decrease the rate of drug release. Methematical analysis of the release kinetics indicated that the nature of drug release from the matrix tablets was dependent on drug diffusion and polymer relaxation and therefore followed non-Fickian or anomalous release. No incompatibility was observed between the drug and excipients used in the formulation of matrix tablets. The developed controlled release matrix tablets of lamivudine, with good initial release (32% in 4th hour) and extension of release up to 14 hours, can overcome the disadvantages of conventional tablets of lamivudine
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Chien YW. Novel drug delivery systems. In: Chien YW, ed. Oral Drug Delivery and Delivery Systems. New York, NY: Marcel Dekker; 1992:139-196.
Vyas SP, Khar RK. Controlled drug delivery: concepts and advances. In: Vyas SP, Khar RK, eds. Controlled Oral Administration. Delhi, India: Vallabh Prakashan; 2002:155-195.
Anthony SF, Clifford HL. Human immunodeficiency virus (HIV) disease: AIDS and related disorders. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison’s Principles of Internal Medicine. New York, NY: McGraw-Hill; 2001:1852-1913.
Betty JD. Human immunodeficiency virus (HIV)—antiretroviral therapy. In: Herfindal ET, Gourley DR, eds. Textbook of Therapeutics: Drug and Disease Management. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:1555-1582.
Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog- related mitochondrial toxicity. Clin Ther. 2000; 22:911-936.
Vargas CI, Ghaly ES. Kinetic release of theophylline from hydrophilic swellable matrices. Drug Dev Ind Pharm. 1999;25:1045-1050.
Ranga RKV, Padmalatha DK, Buri B. Cellulose matrices for zero-order release of soluble drugs. Drug Dev Ind Pharm. 1988;14:2299-2320.
Parojcic J, Duric Z, Jovanovic M, Ibric S. An investigation into the factors influencing drug release from hydrophilic matrix tablets based on novel carbomer polymers. Drug Deliv. 2004; 11:59-65.
Bravo SA, Lamas MC, Salomon CJ. Swellable matrices for the controlled-release of diclofenac sodium: formulation and in vitro studies. Pharm Dev Technol. 2004;9:75-83.
Velasco MV, Ford JL, Rowe P, Rajabi- Siahboomi AR. Influence of drug:hydroxypropyl methylcellulose ratio, drug and polymer particle size and compression force on the release of diclofenac sodium from HPMC matrices. J Control Release. 1999;57:75-85.
Heng PWS, Chan LW, Easterbrook MG, Li X. Investigation of the influence of mean HPMC particle size and number of polymer particles on the release of aspirin from swellable hydrophilic matrix tablets. J Control Release. 2001;76:39-49.